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Abstract 
Over the past decades, effective cancer therapies have resulted in a significant improvement in the 
survival rates for a number of cancers and an increase in the number of cancer survivors. Radiation 
therapy is widely used in the treatment of cancer, and it can induce various cardiotoxicities that differ 
considerably from chemotherapy-induced cardiotoxicity. They occur primarily as late radiation-induced 
complications, several years from the end of anticancer treatment and present as coronary artery dis-
ease, heart failure, pericardial disease, valvular heart disease and arrhythmias. Patients who recovered 
from cancer disease suffer from cardiac complications of anticancer treatment, it affects the quality of 
their lives and life expectancy, especially if the diagnosis is delayed. These patients may present distinct 
symptoms of cardiac injury, resulting from radiation-induced neurotoxicity and altered pain perception, 
which makes diagnosis difficult. This review highlights the need for a screening programme for  patients 
who have undergone radiation therapy and which will subsequently have a potentially profound impact 
on morbidity and mortality. (Cardiol J XXXX; XX, X: xx–xx)
Key words: radiotherapy, ionizing radiation, radiation injuries, cardiotoxicity,  
neoplasms
Introduction
Radiotherapy, along with surgery and chemo-
therapy, is a therapeutic technique used for defini-
tive and palliative treatment of cancer. Currently, 
radiotherapy is a useful tool for the treatment of 
breast cancer, mediastinal lymphomas, head and 
neck tumors, and cancers of the lung, oesophagus, 
thyroid gland, prostate, and the genitals [1]. Cardio-
vascular complications resulting from radiotherapy 
were first noted in the 1970s. In 1978, a study in a 
group of 46 patients who underwent chest radiation 
revealed that radiotherapy led to cardiac fibrosis 
(involving the endocardium, myocardium, and peri-
cardium) which mostly manifested clinically with 
pericarditis [2]. An association between ionizing 
radiation doses delivered to the heart and cardiac 
injuries were first noted in 1983. At the same time, 
a need to reduce the radiation doses applied was 
emphasized [3]. Studies indicated that the patient 
survival rate after effective anticancer treatment 
depended on late complications of the therapy 
delivered [4]. In patients with Hodgkin lymphoma 
who underwent radiotherapy, the most common 
causes of death included a primary or secondary 
cancer and cardiovascular disease (CVD) [5, 6].
At the present time, established radiation-
related cardiovascular complications include coro-
nary artery disease (CAD), valvular heart dis-
ease, pericardial disease, heart failure (HF), right 
ventricular (RV) injury, arrhythmias, peripheral 
arterial disease, systemic hypertension, pulmo-
nary hypertension, and thromboembolic disease 
[7]. These findings are the result of long-term 
follow-up of patients with a history of cancer with 
a relatively good prognosis for survival, particularly 
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Hodgkin lymphoma and early-stage breast cancer 
[8, 9]. A meta-analysis of 25 studies that included 
patients who received anthracyclines as anticancer 
treatment in childhood revealed that adding radio-
therapy increased the rate of asymptomatic systolic 
HF [10]. Similarly, an analysis of adult patients who 
received anthracyclines for the treatment of left-
side breast cancer showed that adding radiation 
therapy increased the risk of HF, which occurred 
in 0.5% of all patients and in 2.6% of those who 
received chemotherapy combined with radiation 
therapy [11].
The mechanism of radiation-related cardiac 
injury is early acute inflammation of small and 
medium-sized vessels, with cardiomyocytes ne-
crosis due to hypoxia as a result of microvascular 
damage and interstitial fibrosis. Reactive oxygen 
species (ROS) produced in irradiated cells play an 
important role in cardiac injury, and they may dam-
age cellular membrane proteins and lipids [12–16].
The rate of radiation-related cardiovascular 
complications depends on several additional risk 
factors, such as total radiation dose (significantly 
higher for doses above 30 Gy), fractional radiation 
doses higher than 2 Gy per day, radiation doses 
delivered to the heart, the heart volume exposed 
to radiation, no shielding during radiotherapy, 
younger age at diagnosis, adjuvant chemotherapy 
(dependent on the total anthracycline dose), pre-
vious CVD, and cardiovascular risk factors [17, 
18]. According to the American Society of Clinical 
Oncology, radiation-related cardiovascular compli-
cations develop in 10–30% of patients at 5 to 10 
years after treatment [19].
For the last three decades, advances in radia-
tion techniques have led to a reduction in the rates 
of radiotherapy complications. This was achieved 
by appropriate treatment planning with the use of 
three-dimensional (3D) imaging techniques, mod-
ern conformal radiation techniques with radiation 
beam intensity modulation (IMRT), and in the case 
of Hodgkin lymphoma, with a reduction of irradi-
ated areas by radiation delivery only to involved 
fields (IFRT) or involved nodes (INRT). These 
methods allow for a reduction in the heart volume 
exposed to radiation [19, 20].
Radiation dose to the heart is now strictly 
controlled in radiotherapy planning systems, and 
details of radiation exposure are available for treat-
ing radiation oncologists in precise dose-volume 
histogram evaluations. Exact dose to each struc-
ture of the heart can also be visualized on each scan 
of planning computed tomography (CT), allowing 
for better prediction of early and late toxicity. Due 
to this progress and an understanding of the as-
sociation between radiation dose and late cardiac 
complications of radiotherapy, doses to the heart 
are now much lower than in the past. In the three 
largest groups of patients treated with radiotherapy 
to the chest, typical mean doses to the heart for 
patients with breast cancer are in the range 1–3 Gy, 
for patients with lymphomas in the range of 1–10 Gy, 
and for patients with lung cancer, 1–20 Gy. These 
doses depend primarily on the anatomical location 
and stage of the tumor, as well as radiation tech-
niques available in treatment facilities.
Coronary artery disease
Exposing the heart to ionizing radiation dur-
ing anticancer therapy increases the risk of CAD. 
Damage to nerve endings caused by neurotoxicity 
of radiation therapy in the radiated fields is a factor 
impeding early diagnosis of CAD due to reduction 
of chest pain sensation in this group of patients. 
The risk of CAD increases with the radiation dose 
administered to the heart [21, 22]. The mechanism 
of radiation-related injury to coronary arteries is 
multifactorial and includes endothelial damage, 
atherosclerotic plaque rupture, thrombosis, and 
vasospasm [7, 12]. Coronary artery lesions associ-
ated with radiotherapy are typically located in the 
ostia and proximal vessel segments. For left- and 
right-sided breast cancer irradiation they mostly 
develop in the left anterior descending artery and 
right coronary artery, respectively, and in the left 
main coronary artery, the left circumflex artery, 
and the right coronary artery after mediastinal 
radiotherapy for Hodgkin lymphoma, correspond-
ing to the areas exposed to radiation [7, 17, 23, 
24]. In addition, myocardial perfusion defects are 
seen regardless of the coronary artery territories, 
which suggests microvascular damage. This was 
shown using technetium-99m sestamibi myocardial 
perfusion scintigraphy in 50% of the observed 
patients at 1 year following adjuvant radiotherapy 
for left-sided breast cancer [25].
Modern radiotherapy techniques are still being 
developed, which creates an opportunity to modify 
and minimize radiation doses delivered to normal 
tissue, thus reducing the rates of cardiovascular 
complications. At the present time, radiotherapy 
is based on 3D or 4D (accounting for respiratory 
motion) treatment planning with dose-volume 
histograms, depicting dose distribution in prede-
fined anatomical areas of the heart. It is possible 
to delineate the contours of the pericardium and 
coronary arteries with the available imaging tech-
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niques, such as CT or magnetic resonance imaging 
(MRI). As a result, it is possible to estimate the ra-
diation dose delivered to the whole heart, coronary 
arteries, atria, ventricles and cardiac conduction 
system [26, 27].
Progression of CAD in these patients may vary. 
The disease may occur early, with symptoms of 
acute coronary syndrome and even sudden cardiac 
death, but it usually develops slowly and is detected 
approximately 15 years after treatment. A study 
based on the observation of 34,825 patients with 
breast cancer treated with radiotherapy in Sweden 
and Denmark in 1976–2006 showed that angina and 
myocardial infarction (MI) occurred with a higher 
rate in patients irradiated to the left breast com-
pared to those irradiated to the right breast. Fur-
thermore, the radiation dose to the whole heart was 
on average 6.3 Gy during left-sided radiotherapy 
and 2.7 Gy during right-sided radiotherapy, show-
ing a relation between the radiation dose delivered 
to the heart and incident CAD [21]. CAD was found 
in 10.4% of patients followed for at least 20 years 
after mediastinal radiotherapy with the radiation 
dose ranging from 25 to 42 Gy [28].
A study performed on an animal model indicat-
ed that radiation therapy accelerated the develop-
ment of coronary artery atherosclerosis related to 
hypercholesterolemia [29]. In addition, observation 
of a large population of patients after treatment 
for Hodgkin lymphoma revealed that angina, MI, 
and HF occurred at a higher rate in patients with 
hypercholesterolemia, diabetes mellitus, and a 
history of smoking. This analysis also showed that 
angina and HF occurred more frequently in patients 
treated at a younger age, below 20 years [6, 30]. A 
retrospective analysis of patients who underwent 
radiotherapy for Hodgkin lymphoma revealed that 
a higher risk of late cardiovascular complications of 
irradiation showed an association with a younger 
age, male sex, radiation dose delivered to the 
whole heart, and dose inhomogeneity [31]. Higher 
radiation dose homogeneity may be obtained using 
modern radiotherapy techniques and is associated 
with a lower risk of cardiac damage for the same 
radiation dose delivered to the heart. It is an im-
portant parameter when planning treatment with 
ionizing radiation.
In primary prevention of progressive coro-
nary disease each patient after chest radiotherapy 
should be screened for classic cardiovascular risk 
factors, with adequate management and correction 
of modifiable risk factors. A model of screening 
for CAD depends on the Systemic Coronary Risk 
Estimation (SCORE) result and accompanying 
symptoms, and among cancer survivors, it does 
not differ from the general population [32, 33]. 
The main issue is the time to start a screening 
program, because radiotherapy leads to premature 
onset of CAD mainly in asymptomatic patients. 
A study on Hodgkin disease survivors, with no 
symptoms of CAD revealed left ventricular (LV) 
segment hypokinesis in rest echocardiography in 
17% of patients who have had mediastinal radia-
tion therapy with high doses of radiation (more 
than 35 Gy) [34].
A recent expert consensus statement from 
European Association of Cardiovascular Imag-
ing and the American Society of Echocardiogra-
phy [17] recommends echocardiographic evalua-
tion in asymptomatic high-risk patients starting 
5 years after radiation exposure and 10 years after 
exposure in the others, with reassessment every 
5 years. According to this document, high-risk pa-
tients should also receive a functional non-invasive 
stress test for CAD detection within 5 to 10 years 
after completion of chest irradiation. This strategy 
was adopted in the present center, and as treadmill 
exercise electrocardiograms (ECGs) may not re-
flect the burden of CAD, patients who are at least 
5 years after radiotherapy are referred for stress 
echocardiography (including the assessment of 
changes in LV global longitudinal strain). 
Apart from stress echocardiography, either 
exercise or dobutamine, perfusion single-photon 
emission CT and MRI may reveal stress-induced 
LV wall motion abnormality [17]. For younger 
patients coronary CT angiography is a valuable op-
tion because of its high negative predictive value. 
Exposure to radiation is still an issue, however 
modern CT scanners allow for dose reduction. 
Another limitation of coronary CT angiography are 
advanced calcifications, which if significant may im-
pede detection of coronary arteries stenosis [35]. 
Cardiac MRI is an excellent method for reliable 
assessment of cardiac structure and function, but it 
poses significant logistic and economic challenges. 
Pharmacological treatment of CAD does not 
differ from the general population, it includes 
acetylsalicylic acid or double antiplatelet therapy 
after stent implantation, statin, beta-blocker and 
angiotensin-converting enzyme (ACE) inhibitor 
or angiotensin receptor blocker (ARB), if not 
contraindicated. Invasive treatment: percutane-
ous coronary intervention (PCI) with stent im-
plantation is recommended in patients with acute 
coronary syndrome or stable CAD refractory to 
pharmacological therapy. Conservative treatment 
in these conditions leads to poorer prognosis [33].
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In reference to cardiac surgery and coronary 
artery bypass grafting (CABG), some studies 
showed increased perioperative risk resulting from 
mediastinal fibrosis [36, 37], but new research 
indicates that previous radiotherapy does not 
increase surgical complications and does not im-
pact  long-term survival comparing to cancer-free 
patients in isolated CABG surgery. The utilization 
of internal thoracic artery for graft was reduced in 
the study group, which worsens outcome of CABG 
in the general population [38]. In patients who have 
undergone prior chest radiotherapy, CT should be 
performed before deciding on CABG to evaluate 
the degree of mediastinal fibrosis and potential 
calcifications in the ascending aorta and aortic arch, 
which could impede implantation of aortocoronary 
grafts. Moreover, regarding potential radiation 
damage to the internal thoracic artery, angiographic 
assessment of this artery should be performed. As 
valvular heart disease could also be a complication 
of radiotherapy, a detailed valve examination is 
necessary before CABG in order to avoid repeated 
sternotomy [38]. In a recent study, patients with 
prior mediastinal radiotherapy referred for surgi-
cal aortic valve replacement have had significantly 
worse long-term survival compared to a matched 
control group [37].
Pericardial disease
Currently, pericardial diseases occur less of-
ten as a complication of chest radiotherapy. These 
conditions include acute pericarditis, chronic 
pericarditis, chronic pericardial effusion, and con-
strictive pericarditis. They mostly develop in 
patients treated with a radiation dose of at least 
50 Gy [39]. Treatment decisions depend on the type 
of pericardial disease and the clinical condition of 
the patient [3, 40].
Common symptoms of acute pericarditis in-
clude fever, chest pain related to body position 
and respiratory movements, pericardial effusion on 
echocardiography, and ST segment elevation and 
PR depression in multiple ECG leads. In a patient 
presenting with acute chest pain or elevated cardiac 
troponin level, it is necessary to rule out acute 
coronary syndrome by ECG and echocardiography 
with LV contractility assessment. Acute exudative 
pericarditis rarely occurs during radiotherapy, and 
it is related to inflammation and necrosis of a tumor 
located near the heart [17]. A study performed on 
an animal model showed that acute pericarditis 
developed within 6–48 h after irradiation with 
a 20–40 Gy dose [40]. Delayed acute pericarditis, 
either symptomatic or asymptomatic, may develop 
in 2–5% of patients at 2–145 months after chest 
radiotherapy. This condition very rarely leads 
to cardiac tamponade which requires pericardial 
drainage [7].
Hemodynamically stable patients are usually 
managed medically, initially with non-steroidal 
anti-inflammatory drugs and colchicine, followed 
by glucocorticoids and immunosuppressive drugs if 
the first-line treatment is ineffective. Spontaneous 
clearance of pericardial effusion usually takes up to 
2 years [17]. Data from patients treated with older 
radiotherapy techniques indicate that pericardial 
disease developed in 10–12% of patients at 6 to 18 
months after irradiation, with acute pericarditis in 
35% of these cases [3, 40].
Patients with impending or actual cardiac tam-
ponade require invasive treatment. Percutaneous 
pericardiocentesis with extended catheter drainage 
is considered the safest method to remove excess 
pericardial fluid in cancer patients, even in those 
with thrombocytopenia [41, 42]. Surgical drainage 
is an alternative approach but is associated with a 
higher perioperative risk.
Chronic pericarditis may occur from 6 months 
to 15 years after completion of radiotherapy and 
develops in up to 20% of patients treated with high 
radiation doses. This process is associated with 
organization of fibrinous exudates, fibrous adhe-
sions, and collagenous thickening, predominantly 
of the parietal pericardium. The incidence of peri-
cardial layer thickening following radiation therapy 
increases with time, affecting 33% of patients 
after more than 20 years [28, 43]. Its occurrence 
depends on the radiation dose administered to the 
whole heart, including both the right and the left 
atrium [24, 44].
Constrictive pericarditis develops in 4% to 
20% of radiotherapy patients, particularly those 
treated with older techniques, and it usually re-
quires pericardiectomy [17,43, 45, 46]. In suspicion 
of constrictive pericarditis, constrictive cardiomyo-
pathy should be ruled out by echocardiography, 
chest X-ray, CT or MRI revealing thickening of 
pericardium, calcifications, abnormal interventricu-
lar septum movement, abnormal mitral valve flow 
pattern, or by right heart catheterization if these 
tests are inconclusive [47].
In the case of pericardial effusion, and es-
pecially its recurrence, it may be problematic to 
determine whether it is caused by radiotherapy, 
tumor progression or infection. Biochemical and 
microbial blood sample tests, polymerase chain 
reaction (PCR) are useful, but in some cases 
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pericardial fluid examination may be required in 
recognizing  pericarditis etiology. According to 
the newest European Society of Cardiology (ESC) 
guidelines regarding pericardial disease, diagnos-
ing of etiology should be performed in patients, who 
present with fever > 38°C, subacute development 
of symptoms, > 20 mm of fluid in imaging and low 
response to acetylsalicylic acid/non-steroid anti-
inflammatory drug treatment [48]. 
Imaging and comparing of effusion density in 
pericardial cavity may be helpful in recognizing 
etiology: protein-rich fluid, consisting of blood e.g. 
in aortic aneurysm rupture or aortic dissection; 
high density fluid in lymph leakage; pericardium 
thickening in inflammation or thickening with 
calcification in constrictive pericarditis. Imaging 
by CT or MRI may reveal direct neoplastic infiltra-
tion or metastasis. Positron emission tomography 
individually or combined with CT (recommended), 
is helpful in the diagnoses of neoplasmatic etiology 
of pericarditis if fluodexyglucose uptake in tumor 
cells is observed. 
The most common primary cancer in peri-
cardium is mesothelioma, and benign tumors are 
lipoma and fibroma. Secondary malignancy comes 
mostly from lung cancer, breast cancer, melanoma, 
lymphoma and leukemia. The presence of cancer 
cells in pericardial fluid is associated with worse 
outcomes in lung cancer patients but such an asso-
ciation was not found in breast cancer patients [42]. 
Generally, the utility of the assessment of cancer 
markers in serum and in pericardial fluid has still 
not been proven, but a positive result of e.g. EGFR 
mutation test in pericardial effusion in lung cancer 
influences the decision about targeted anticancer 
therapy implementation [47]. Pericardium biopsy 
allows for histological diagnosis of cancer. Among 
patients with recognized cancer, the spreading of 
malignancy is a reason of pericarditis in approxi-
mately 30% of patients [47].
In cancer etiology of pericarditis, intrapericar-
dial administration of cytostatic or sclerotic agent 
may decrease a frequency of fluid recurrence. As 
a palliative treatment, radiotherapy or pleurop-
ericardiotomia alleviates symptoms of recurrent 
pericarditis.
Valvular heart disease
Valvular heart disease complicating radiother-
apy develops in 10% of patients. Radiation-induced 
valve abnormalities are characteristically distrib-
uted, with thickening and calcifications located at 
the basal and medial parts of the leaflets, while 
leaflet tips and commissures are spared, allowing 
distinction from rheumatic disease. Calcification of 
the mitro-aortic curtain, the junction between the 
anterior mitral leaflet valve and the aortic root, is 
also characteristic for post-radiation damage [49]. A 
retrospective analysis of post-radiotherapy patients 
with Hodgkin lymphoma showed valvular lesions 
in 6.2% patients after an average 22 years of ob-
servation, with aortic stenosis in more than a half 
of these patients [22]. However, in another study 
of patients followed up for at least 20 years after 
mediastinal radiotherapy with a minimal radiation 
dose of 35 Gy, aortic stenosis was found in 16%, 
mitral regurgitation in 60%, and tricuspid regur-
gitation in 4% of patients in the study group [28]. 
Valvular lesions are more common on the left side 
of the heart than on the right side, independently 
of radiation dose [50]. In cases of severe valvular 
lesions requiring invasive treatment, transcath-
eter methods (e.g., transcatheter aortic valve 
implantation) are considered to be safer compared 
to conventional valve surgery due to mediastinal 
fibrosis and aortic calcifications which are common 
after radiotherapy.
Left ventricular dysfunction
Radiotherapy-induced cardiac damage leads to 
myocardial fibrosis [39, 51] which mostly results 
in LV diastolic dysfunction. The main mechanism 
underlying cardiomyocytes injury is microvascular 
damage. In addition, combining radiotherapy with 
cardiotoxic chemotherapy using anthracyclines, 
especially in young patients and in females with 
breast cancer, may also lead to LV systolic dysfunc-
tion. Advanced myocardial fibrosis may predispose 
to restrictive cardiomyopathy phenotype observed 
after radiation therapy, with the presence of severe 
diastolic dysfunction and symptoms of HF. A dif-
ferential diagnosis from constrictive pericarditis 
is recommended by echocardiography, CT, MRI, 
and right heart catheterization, if required. The 
principle in diagnosis is reduced myocardial elastic-
ity, that is due to impaired myocardial relaxation 
in restrictive cardiomyopathy and constricted 
chambers by pericardium with normal diastolic 
function in constrictive pericarditis. In restrictive 
cardiomyopathy transthoracic echocardiography 
reveals normal or thickened left and right ventricle, 
normal or reduced LV cavity, enlarged atria, restric-
tive transmitral filling pattern (E/A ratio > 2), and 
reduced peak early-diastolic mitral-annular veloci-
ties in tissue Doppler (e’ < 8 cm/s) independent 
of respiration. Other imaging modalities, as CT or 
www.cardiologyjournal.org 5
Izabela Nabiałek-Trojanowska et al., Cardiovascular complications after radiotherapy
MRI may detect structural changes in myocardium 
e.g. fibrosis and unthickened pericardial layer. Car-
diac catheterization reveals increased RV systolic 
pressure (above 50 mmHg), and LV end-diastolic 
pressure (LVEDP) by 5 mmHg higher than RV 
end-diastolic pressure (RVEDP) [47]. 
Left ventricular systolic function is routinely 
assessed by LV ejection fraction (LVEF) measure-
ment during echocardiography. The recommended 
method to evaluate LVEF is 3D echocardiography. 
If this method is not available, LVEF should be as-
sessed by the 2D biplane Simpson method, based 
on contouring of the LV cavity during systole and 
diastole in the apical 4- and 2-chamber views. 
Disadvantages of this method include its depend-
ence on the appropriate angle of transducer and 
the fact that it reveals relatively late impairment 
of LV systolic function.
A new method of an increasing significance 
is the assessment of LV global longitudinal strain 
(GLS) by 2D speckle tracking echocardiography 
(STE). In this technique, a percentage of cardiac 
muscle shortening in the longitudinal layer is as-
sessed during one or three cardiac cycles. Newer 
software allows for distinguishing the inner and 
outer myocardial layers, what is important for di-
agnosis. Abnormalities within the inner (subendo-
cardial) layer indicate mainly CAD etiology, but can 
be also present in patients with chemotherapy-in-
duced cardiotoxicity. In turn, abnormalities within 
the outer (subepicardial) layer indicate myocardial 
inflammation, rarely cardiotoxicity. Apart from 
the longitudinal muscle layer, motion in the radial 
and circumferential myocardial layers may also be 
tracked by STE. These methods are also used for 
the assessment of RV function. 
An analysis of patients after radiotherapy for 
chemotherapy-naive early stage of breast cancer 
showed a decrease in GLS and apical longitudinal 
strain after radiotherapy for left-sided breast 
cancer. In this group of patients, a compensa-
tory increase in basal longitudinal strain was also 
observed. Other conventional echocardiographic 
parameters were not sensitive enough to show 
any changes of the LV systolic function. In patients 
after radiotherapy for right-sided breast cancer, 
speckle tracking analysis revealed decreased 
longitudinal strain in basal anterior segments 
[52]. The observed changes in longitudinal strain 
corresponded to the irradiated region of the heart. 
The study showed that assessment of longitudinal 
strain by STE is a more sensitive method in reveal-
ing LV systolic dysfunction compared to LVEF 
measurements and visual assessment of segmen-
tal wall motion abnormalities. A meta-analysis 
of 16 studies that included patients with HF, acute 
MI, and valvular heart disease showed a superior 
predictive value of GLS assessment compared 
to LVEF for predicting major adverse cardiac 
events [53].
A study of patients with Hodgkin lymphoma 
treated with a radiation dose of at least 35 Gy in 
comparison to the Framingham study population 
showed a decrease in the LV fractional shortening 
to less than 30% in 36% of patients in the study 
group and in 3% of subjects in the Framingham 
study population [28]. An MRI study showed that 
late gadolinium enhancement corresponded to the 
radiation fields within the heart, and that delivery 
of a radiation dose to the heart had an effect on the 
occurrence of radiation-induced cardiomyopathy 
[54]. A study in breast cancer patients revealed 
that the increase in the serum high-sensitive 
troponin T level depended on the total radiation 
dose delivered to the whole heart and the LV. Long-
term implications of this finding are unknown and 
require further studies [55].
In 2011, Polish National Team of Cardiologic 
and Oncologic Supervision published recommen-
dations regarding care for breast cancer patients 
[56]. The emphasis was put on prevention, early 
diagnosis, by highly specific and sensitive methods, 
and treatment of CVD. The limit of significant LV 
dysfunction was set on a drop of LVEF of 15%, to 
value less than 50%.
According to the 2016 ESC guidelines [7], an 
LVEF decrease by means of echocardiography of 
more than 10% to a value below the lower limit 
of normal values (LVEF < 50%) suggests cardio-
toxicity. And a relative GLS reduction by more 
than 15% compared to the baseline may suggest 
the risk of cardiotoxicity. Both guidelines recom-
mended ACE inhibitor therapy in patients with 
LVEF lower than 50%. Newer guidelines added 
monitoring of B-type natriuretic (BNP) peptide 
or NT-pro-BNP concentration to evaluate cardiac 
dysfunction and make decisions on starting phar-
macological cardiovascular therapy or changing 
anticancer treatment. 
These guidelines refer to complications of 
chemotherapeutic agents, and it should be noted 
that specific guidelines regarding radiation-induced 
heart disease are lacking. According to the 2017 
American Society of Clinical Oncology (ASCO) 
guidelines, patients who were exposed to at least 
30 Gy of irradiation containing the heart in the irra-
diated field, or those who underwent radiotherapy 
with less than 30 Gy with the heart in the irradiated 
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field but combined with anthracycline treatment 
are at increased risk of cardiac dysfunction [57].
If LV systolic dysfunction is detected, it is man-
aged medically similar to other etiologies of HF, 
mostly with beta-blocker, ACE inhibitors or ARBs 
[51]. In patients with end-stage HF who underwent 
radiotherapy, the previous radiation therapy is 
not a contraindication to cardiac transplantation. 
Despite technical difficulties in performing the 
surgery due to severe mediastinal fibrosis in the 
irradiated regions, the survival rate after cardiac 
transplantation does not differ significantly from 
life expectancy after cardiac transplantation in 
radiotherapy-naive patients [36].
Right ventricular dysfunction
The RV is located immediately behind the 
anterior chest wall and thus it is most prone to 
the adverse effects of mediastinal radiotherapy. 
Although the latest cardiooncological guidelines 
mostly discuss LV function, it has been recently 
suggested that cardiovascular morbidity and mor-
tality associated with oncological treatment is also 
related to the condition of the RV [58].
Radiation-induced RV damage is mainly caused 
by myocardial fibrosis and remodeling, damage to 
blood vessels, and accelerated coronary artery 
atherosclerosis [58]. In addition, radiotherapy- 
-induced pericardial fibrosis may induce RV dias-
tolic dysfunction followed by systolic dysfunction, 
as the RV is subjected to low afterload under nor-
mal conditions [59].
The risk factors for radiotherapy-induced dam-
age to the RV include total and fractional radiation 
dose, irradiation method, tumor location, and con-
comitant diseases [58]. In breast cancer patients, 
the number of individuals with RV systolic dysfunc-
tion increases with time following treatment with 
anthracyclines, trastuzumab and/or radiotherapy 
[60]. Examination using the novel method of ultra-
sonic tissue characterization showed an increase 
in myocardial echogenicity related to the radiation 
dose. The study was performed in patients with 
left breast cancer and showed that the RV free wall 
was exposed to the highest radiation dose during 
radiotherapy [61]. The increase in RV free wall 
echogenicity was accompanied by a decreased tri-
cuspid annular plane systolic excursion (TAPSE).
Right ventricular structure and function may 
be assessed by echocardiography and MRI. Echo-
cardiographic parameters include TAPSE, RV 
fractional area change, lateral tricuspid annular 
systolic velocity (RV S’), RV free wall longitudinal 
strain, and RV wall thickness. The gold standard 
imaging tool is MRI which allows for precise evalu-
ation of the RV structure and function including 
end-diastolic volume, end-systolic volume, and RV 
ejection fraction [62].
Arrhythmias
Electrocardiographic abnormalities and ar-
rhythmias are recognized in 16–36% patients with 
a history of radiotherapy [7], including bradyar-
rhythmias, tachyarrhythmias, and various conduc-
tion disturbances. These arrhythmias are usually 
related to fibrosis involving the atria and the con-
duction system. An association was found between 
arrhythmic events and the radiation dose in the 
right atrium, the left atrium and the whole heart 
in patients treated with high dose radiation therapy 
for non-small-cell lung cancer [44].
Chemotherapy combined with radiotherapy 
may increase the arrhythmic risk. Many chemo-
therapeutic agents lead to the QTc interval pro-
longation (in particular arsenic trioxide, tyrosine 
kinase inhibitors, and doxorubicin). Electrolyte 
disturbances which are common during anticancer 
treatment (both primary and secondary to vomit-
ing, diarrhoea and skin lesions after radiotherapy) 
and administration of other drugs that increase 
the QTc interval (antiemetics, antibiotics, anti-
mycotics, psychotropic agents, and antiarrhythmic 
drugs) also favour arrhythmic events [7, 28].
Atrial fibrillation (AF) is the most common 
supraventricular arrhythmia induced by radio-
therapy, chemotherapy and/or surgical treatment. 
Indications for chronic oral anticoagulation have 
to be considered in patients with AF, which may 
be problematic due to an elevated risk of both 
thromboembolic events and bleeding complica-
tions in patients with malignancies. Low molecular 
weight heparins, vitamin K antagonists, and novel 
oral anticoagulants may be used for anticoagulation 
[63, 64]. It should be noted that the CHA2DS2-VASc 
and HAS-BLED risk scores to evaluate the risk 
of thromboembolism and bleeding complications, 
respectively, have not been validated in cancer 
patients. 
Radiotherapy-induced ventricular arrhythmias 
are caused by myocardial ischemia and LV dys-
function [7]. Similarly, sinus node dysfunction and 
atrioventricular conduction disturbances are the 
result of ischemia, myocardial fibrosis, and direct 
damage to the cardiac conduction system caused 
by irradiation [12, 43]. Right bundle branch block 
is most frequently seen after chest radiotherapy 
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because the right bundle is situated just under the 
endocardium and is most susceptible to irradiation-
induced damage [16].
In summary, factors favouring the occurrence 
of arrhythmia such as previous heart disease, QTc 
prolonging drugs, electrolyte disturbances, kidney 
function, thyroid hormone level, and impaired he-
patic metabolism have to be taken into considera-
tion in patients undergoing radiotherapy. Serious 
arrhythmias and conduction disturbances need to 
be treated by either drug therapy or cardiac device 
implantation.
Peripheral arterial disease
In addition to the effect on the heart, radio-
therapy delivered to the neck and mediastinum may 
also damage blood vessels located in the irradiated 
area. Mechanisms include direct damage to vessel 
walls, injury of vasa vasorum, fibrosis, and acceler-
ated atherosclerosis [65]. Significant atheroscle-
rotic lesions in either carotid or subclavian arteries 
were observed in 7.4% of patients at 17 years after 
radiation therapy. The average patient age at the 
time these vascular lesions were diagnosed was 
34 years, and stroke or a transient ischemic at-
tack occurred at an average age of 51 years [22]. 
Pathological lesions in femoral arteries developed 
not earlier than 5 years after radiotherapy of the 
abdominal and pelvic regions [66, 67]. In addition, 
irradiation of the abdominal cavity may lead to the 
development of arterial hypertension mediated by 
damage to renal vessels.
The severity of arterial damage depends on 
radiation dose and time since treatment [68]. It 
was also shown that conventional CAD risk factors 
including hypertension and hypercholesterolemia 
have a synergistic effect on the development of 
radiation-induced arterial disease, and this risk 
may be minimized with proper treatment [67]. 
Radiation-induced arterial disease is managed using 
the same approach as atherosclerotic disease, and 
the treatment includes use of acetylsalicylic acid, 
statin, and percutaneous and surgical interventions. 
Invasive treatment outcomes are similar in patients 
with or without a history of malignancy [66].
Arterial hypertension  
and orthostatic hypotension
Irradiation of the head or neck may result in 
disruption of baroreflex, which in the chronic phase 
is characterized by severe labile blood pressure 
(BP), and this condition is commonly referred to as 
the syndrome of baroreflex failure. The baroreflex 
normally functions via carotid stretch receptors 
to maintain heart rate and BP. The mechanism of 
radiation-induced baroreflex failure is  direct dam-
age of carotid sinus receptors and their afferent 
vagal branches or accelerated atherosclerosis and 
fibrosis within arterial walls. Decreased baroreflex 
sensitivity and inefficient inhibitory activity may 
result in increased sympathetic tone. More rarely, 
inadequate efferent baroreceptor activity may lead 
to orthostatic hypotension with syncope, BP drop 
during sleep and bradycardia. 
Baroreflex failure syndrome presents with 
headache, anxiety, emotional lability, tachycardia, 
hypertension, orthostatic lightheadedness, and/or 
hypotensive episodes. There may be severe BP 
elevation, even exceeding 250 mmHg, which may 
cause complications such as cerebral hemorrhage 
or encephalopathy. The onset of increased BP may 
occur days or weeks from completion of radio-
therapy [69]. In differential diagnosis tests to rule 
out secondary causes of hypertension (e.g., renal 
artery stenosis or parenchymal disease, pheo-
chromocytoma, other endocrinopathies) should 
be performed. 
Cardiovascular dysfunction in these patients 
can be detected by ambulatory BP monitoring 
demonstrating abnormalities in resting BP and 
increased BP variability. To confirm baroreflex fail-
ure, deep breathing, Valsalva maneuver and tests 
with intravenous administration of phenylephrine 
or sodium nitroprusside show abnormal BP pat-
tern and a lack of reflex brady- and tachycardia in 
response to BP changes. 
In acute phase primary treatment is antihy-
pertensive therapy and in chronic phase inhibition 
of central noradrenergic neurotransmission (e.g. 
clonidine) is recommended. Orthostatic and post-
exercise hypotension resulting from baroreflex 
disorder may be challenging in management of 
hypertension. Implantation of pacemaker should be 
considered in patients with malignant bradycardia 
due to vagotonia, and supplementation of fludrocorti-
sone and dietary salt in case of hypotension [69–75].
Impaired cardio-autonomic functions which 
were not apparent clinically were shown by Goyal 
et al. [72] in neck irradiated patients due to cancer 
disease. The authors evaluated heart rate variabil-
ity with time domain analysis of 5 min ECG record-
ing. Postural cardiovascular reflexes were studied 
with changes in BP and heart rate with the lying 
to standing test. The present study revealed a re-
duction in overall time domain measures of heart 
rate variability and weakened postural reflexes in 
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neck irradiated patients. Whether decreased heart 
rate variability in neck irradiated patients reflects 
an independent risk of cardiovascular morbidity 
requires further investigation. Nevertheless, the 
dose of radiation delivered to the carotid sinus 
should be monitored and restricted, as well as ra-
diation oncologists should be aware of baroreflex 
failure syndrome, as they often could be the first 
to diagnose it and detect it early. 
Summary
Ongoing advances in oncology and treatment 
of malignant hematological diseases lead to the 
development of new therapeutic options that in-
crease the proportion of patients with long-term 
survival chances. This increase in life expectancy 
of cancer survivors has led to an increased inci-
dence of long-term complications of anticancer 
therapy, including adverse cardiovascular effects of 
radiotherapy. The aims of cardiooncology include 
the prevention, diagnosis, and treatment of CVDs 
in the population of oncological patients [7, 62, 76]. 
For patients treated with radiation therapy, there is 
a need for accurate recommendations regarding the 
planning and extent of cardiac screening for early 
diagnosis and effective treatment of cardiovascular 
complications of radiotherapy [5, 77, 78]. 
Currently, available data are provided from 
breast cancer and Hodgkin lymphoma groups, who 
reach relatively long-term survival. It is necessary 
to identify groups of patients with higher risk of 
radiation-induced cardiovascular complications 
and prepare for them a follow-up plan. It should be 
taken into consideration that assessment of cardio-
vascular risk based on the radiation dose delivered 
to the heart or the volume of the irradiated heart by 
comparing groups of patients treated with older and 
newer methods of radiotherapy is difficult, because 
of relevant differences in radiation techniques. 
Anyway, according to ASCO guidelines based on 
meta-analysis of available research, minimizing 
doses delivered to heart and volume of the irradi-
ated heart is an essential step in the prevention 
of long-term complications of radiotherapy [57]. 
In patients who have undergone chest radia-
tion therapy, evaluation based on signs and symp-
toms and echocardiographic surveillance should be 
implemented, starting 5 years after treatment in 
high-risk patients and 10 years in all other patients. 
Further reassessment should be performed every 
5 years. Even if asymptomatic, high-risk patients 
should also be referred for functional non-invasive 
stress tests within 5 to 10 years after completing 
irradiation therapy [17, 42]. Pregnant women and 
those who are planning pregnancy should be care-
fully monitored, as gestation may unmask subclini-
cal cardiotoxicity [35].
Another important issue is the treatment of 
comorbidities and reduction of modifiable cardio-
vascular risk factors necessary among those pa-
tients. According to the ESC guidelines regarding 
cardiovascular prevention for cancer survivors, 
recommendations include healthy diet, smoking 
cessation, reduction of body weight and regular 
aerobic exercises, which are especially helpful in 
prevention and treatment of cardiotoxicity [79]. 
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